"OneStart is a grassroots initiative that ushers in fresh entrepreneurial blood."
– Nature Biotechnology
Applications for the 2017 program are paused, and we will re-open the program in 2018
What is OneStart?
OneStart is the world’s largest life sciences and healthcare startup accelerator program - welcoming ideas focused on the improvement of human health including; therapeutics, diagnostics, software, devices, research tools, and more.
Our focus is it to cultivate early-stage entrepreneurship among young and disruptive healthcare innovators and to that end we limit the participation of applicants to 35 years old or younger.
We welcome ideas and businesses at all stages of development, from the very early to more mature (see our FAQs). Our programme provides extensive mentoring and support up to 70 teams each year (not just the winner). As a result, each year multiple entrants secure follow-on funding.
There is absolutely no cost to participate, and you retain full control and ownership of your business. Moreover, teams will be given access to executives from the leading pharmaceutical companies, venture capital firms, and consultancies among other resources. Current mentors come from SR One, Takeda Ventures, Bristol-Myers Squibb, GSK, Roche, AstraZeneca, MedImmune, Boehringer Ingelheim, Teva Pharmaceutical Industries, McKinsey & Co., Silicon Valley Bank, and many more (see some of our mentors here).
A judging panel of industry experts will award the Grand Prize to the team that has the most potential to commercialise their idea and improve the lives of patients.
The Grand Prize
The Grand Prize for OneStart Americas is US$150k, and £100k for OneStart Europe - which welcomes applications from the rest of the world (such as Asia-Pacific, Africa, Middle East, etc). Both prizes are non-dilutive and come with free lab space and extensive follow-on mentoring.
Beyond the Prize
Each year many teams (not just the winners) raise follow-on funds, often during the course of the programme – all thanks to the extensive mentoring, education and industry presence.
OneStart 2015 Archives
Two separate strands: Americas and Europe (+ rest of the world)
There are two parallel strands of the competition each with a separate winner:
OneStart on pause:
OneStart is currently paused for the 2016/2017 program as we restructure the program.
Our aim is to re-open the program for applications on 1 October 2017.
Founder, CEO - OBR, OneStart
Yvette Lu, DPhil
Senior VP, Business Development, OBR
Jens Eckstein, PhD
President, SR One
Partner, SR One
Independent corporate venture capital arm of GlaxoSmithKline.
SR One invests globally in emerging life science companies that are pursuing innovative science with significant impact on medical care. We've invested over $830MM in the health care industry.
We've founded OneStart with the Oxbridge Biotech Roundtable because of our shared missions of catalysing entrepreneurship. Together with OBR, we firmly believe that we can have a positive impact on human health by supporting visionary founders. We see OneStart as a vehicle to that end.
Find out more at srone.com
A professional worldwide platform for innovators.
Our mission is to bridge the gaps between industry and academia to move ideas forward.
We founded OneStart with SR One so that we could unlock and facilitate the latent entrepreneurship in younger scientists. By marrying generous capital support with deep industry experience we hope OneStart sets many dozens of companies in motion each year, each positively impacting human health.
Find out more at oxbridgebiotech.com
Email us at email@example.com